tocilizumab
roche
['toci', 'tocilizumab']
benavides et al. "optimisation" of tocilizumab in gca. dose decreased or interval increased. 231 patients. sustained remission 78.2% optimised group (vs 66.7%). #acr22 abstr#0474 
Rheumatologist @stjamesdublin , Associate Professor @tcddublin , Acute Medicine, Vasculitis, ILD, Retired @Emeunet Executive Committee member, @rheum_covid CASC